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This double bind study was aimed at the Prevention of 
I/ reinfarction 21 reoccclusion of the culprft coronary 
artery, after reperfusion in acute myocardial Pnfarction 
(AH), by flurbiprofene (Fl), a non steroidal anti-inflam- 
matory agent with potent anti-platelet action. 464 pa- 
tients (Pts) o in whom coronary pa cy bad been demonstra- 
ted by a coronary ang~o~ram perfo d witbin 24 hours 
after eucceesfull reperfusion obtained either by early 
((6 hours) thrombolysis or an ioplasty or both. were 
randomized into 2 groups (Gr). Gr% (264 Pts) received 50 
mg b.1.d. of F¶ and GrIf (230 Pts) rece<ved lacebo. At 6 
month follow-up, 5 Pts had died (2 in GE-%, 3 
low mortality rate (1.1%) probably due to tke Pts selec- 
tion. Recurrent HP in the same area was decreased by 91 % 
in Grl (9/233 : 3 X) as compared to GrII (2r(i228 : 10.54t) 
(p<.OOlj . Angfoplaety and coronary by- 
by 51 % (39/233 : 17 %n GrI vs 75/228 : 33 X fn GrfP, 
pc.001). Coronary angiogram perfo 
15 X ; GrfI : 
minor hemorragis 
concomittant trea nt with oral anticoagulants prescri- 
bed fn most Ptsr c more frcquenr in Grl (311’233 : 13 
Conclusion : Although It did not seem to influence the 
reocclusion rate, ne in Pts who benifited from 
as highly effective at 
decreasing IL/ recurrence of infarction 21 need for angio- 
plasty and surgical by-pass. 
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